Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
0.4252
Oct 21 • 5:55 AM ET Dollar change+0.0256 Percentage change(6.41%)
Index
-
Market Cap
0.89M
Enterprise Value
-3.69M
Income
-21.15M
Sales
4.31M
Book/sh
2.41
Cash/sh
2.67
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
24
IPO
Aug 01, 2000
P/E
-
Forward P/E
-
PEG
-
P/S
0.21
P/B
0.18
P/C
0.16
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.86
Quick Ratio
0.49
Current Ratio
0.49
Debt/Eq
0.22
LT Debt/Eq
0.00
Option/Short
No / No
EPS (ttm)
-14.29
EPS next Y
-6.01
EPS next Q
-2.67
EPS this Y
-306.38%
EPS next Y
87.24%
EPS next 5Y
15.90%
EPS past 3/5Y
63.80% 45.78%
Sales past 3/5Y
-2.42% -2.71%
EPS Y/Y TTM
85.37%
Sales Y/Y TTM
-62.17%
EPS Q/Q
70.48%
Sales Q/Q
-100.00%
Insider Own
17.07%
Insider Trans
0.00%
Inst Own
32.40%
Inst Trans
-15.90%
ROA
-87.76%
ROE
-693.93%
ROIC
-450.54%
Gross Margin
97.71%
Oper. Margin
-833.40%
Profit Margin
-490.33%
SMA20
-36.90%
SMA50
-61.40%
SMA200
-95.59%
Trades
Shs Outstand
1.95M
Shs Float
1.73M
52W High
33.60 -98.73%
52W Low
0.32 30.83%
Volatility
22.02% 13.61%
ATR (14)
0.11
RSI (14)
14.85
Beta
3.25
Rel Volume
0.05
Avg Volume
235.01K
Volume
543
Perf Week
-29.11%
Perf Month
-57.48%
Perf Quarter
-90.90%
Perf Half Y
-96.54%
Perf YTD
-97.85%
Perf Year
-98.65%
Perf 3Y
-99.50%
Perf 5Y
-99.99%
Perf 10Y
-99.99%
Prev Close
0.40
Price
0.43
Change %
6.41%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAITIN KENNETH IDirectorMar 31 '26Buy0.5510,0005,48711,407Apr 01 07:51 AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
PresidentMr. James E. Dentzer
M.B.A.Ms. Diantha Duvall CPA
Chief Development OfficerDr. Jonathan B. Zung Ph.D.
Vice President of Technology Management & Intellectual PropertyMr. Mark W. Noel
Senior Director of Human ResourcesMs. Rachel Blasbalg